Increased or abnormally regulated cell proliferation plays an important role in carcinogenesis. Bombesin like peptides are growth factors for a number of cell types, including bronchial epithelial cells. A number of studies in animal models have demonstrated that pulmonary carcinogens, including tobacco smoke, can increase the level of bombesin like peptides in the lung. Studies in humans have demonstrated elevated levels of bombesin like peptides in the lower respiratory tract of clinically normal smokers: a subset of whom display levels outside the range found in nonsmokers. Urinary levels of bombesin like peptides appear to identify individuals with elevated lower respiratory bombesin like peptides. There hypotheses will be tested: 1. Elevated levels of bombesin like peptides identify individuals at high risk for the development of lung cancer. 2. Smoking cessation and/or treatment with chemopreventive agents may lower bombesin like peptide levels along with lung cancer risk. 3. The bombesin like peptide found in smokers may be a new member of this peptide family.
Specific aims i nclude: 1. Cross sectional studies of bombesin like peptide levels in lung cancer and controls. 2. Prospective analysis of a cohort of moderate to high risk smokers. 3. Serial analysis of bombesin like peptide levels in smoking cessation and chemoprevention studies. 4. Molecular characterization of bombesin like peptides in urine and bronchoalveolar lavage.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-03
Application #
3751692
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 435 publications